Since being diagnosed in 2013, Michael Broad has taken part in a number of clinical trials to help find ways of alleviating symptoms and slowing progression of Parkinson’s.
We don’t typically think much about walking or keeping balance unless we have trouble with these activities. That’s because we don’t have to think about them, it’s automatic. Parkinson’s can interrupt these automatic connections and cause walking and balance problems, especially in people who live with the disease for many years.
After a Parkinson’s diagnosis, one of the first questions a person asks is, “What is going to happen to me?” People with Parkinson’s disease understandably want to know how their symptoms will change over time.
Many clinical trials use a placebo comparison to evaluate the effect of a new drug or therapy. Some people get the active intervention and some get an inactive “fake” treatment that looks the same as the real thing. What is a placebo? Is it a good thing? Can a placebo make you feel worse? From Michael J. Fox Foundation for Parkinson’s Research website.
Doctor Rachel Dolhun is movement disorder specialist and vice president of medical communications at the MJFF. In this video, she talks about depression and anxiety in Parkinson’s disease. How are depression and anxiety treated? What are the tips to manage depression and anxiety?
Results are in from a study of glial cell line-derived neurotrophic factor (GDNF), a “brain fertilizer” that some scientists believe may help protect dopamine cells and improve Parkinson’s symptoms. Many news reports are citing the findings as miraculous, but the response could be due to placebo effect.
Gene therapy is a hot topic in Parkinson’s disease. Researchers are now testing this novel approach in clinical trials of people with mid- to late-stage Parkinson’s. These therapies are intended to treat movement symptoms, lessen levodopa needs and, in turn, limit possible medication complications.
We are happy to announce our support to the upcoming new phase of the pet tracer project of AC IMMUNE, a Swiss biopharmaceutical company.
New York’s first medical marijuana dispensary opened in January 2016. This news understandably led the patient and physician communities to ask a number of research and clinical questions about marijuana and Parkinson’s.
Cognitive impairment, disturbance of memory, thinking and/or language abilities, is a non-motor symptom that can be associated with Parkinson’s. Cognitive disturbances can arise at any time in the course of Parkinson’s disease (PD) and vary widely in severity.